343 related articles for article (PubMed ID: 19384000)
1. In vivo dosimetry in the urethra using alanine/ESR during (192)Ir HDR brachytherapy of prostate cancer--a phantom study.
Anton M; Wagner D; Selbach HJ; Hackel T; Hermann RM; Hess CF; Vorwerk H
Phys Med Biol; 2009 May; 54(9):2915-31. PubMed ID: 19384000
[TBL] [Abstract][Full Text] [Related]
2. Uncertainties in alanine/ESR dosimetry at the Physikalisch-Technische Bundesanstalt.
Anton M
Phys Med Biol; 2006 Nov; 51(21):5419-40. PubMed ID: 17047261
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry.
Su Y; Davis BJ; Furutani KM; Herman MG; Robb RA
Phys Med Biol; 2007 Jun; 52(11):3105-19. PubMed ID: 17505092
[TBL] [Abstract][Full Text] [Related]
4. Ir-192 HDR transit dose and radial dose function determination using alanine/EPR dosimetry.
Calcina CS; de Almeida A; Rocha JR; Abrego FC; Baffa O
Phys Med Biol; 2005 Mar; 50(6):1109-17. PubMed ID: 15798311
[TBL] [Abstract][Full Text] [Related]
5. In vivo alanine/electron spin resonance (ESR) dosimetry in radiotherapy of prostate cancer: a feasibility study.
Wagner D; Anton M; Vorwerk H; Gsänger T; Christiansen H; Poppe B; Hess CF; Hermann RM
Radiother Oncol; 2008 Jul; 88(1):140-7. PubMed ID: 18420296
[TBL] [Abstract][Full Text] [Related]
6. Development of a TLD mailed system for remote dosimetry audit for (192)Ir HDR and PDR sources.
Roué A; Venselaar JL; Ferreira IH; Bridier A; Van Dam J
Radiother Oncol; 2007 Apr; 83(1):86-93. PubMed ID: 17368842
[TBL] [Abstract][Full Text] [Related]
7. In vivo dosimetry using a linear Mosfet-array dosimeter to determine the urethra dose in 125I permanent prostate implants.
Bloemen-van Gurp EJ; Murrer LH; Haanstra BK; van Gils FC; Dekker AL; Mijnheer BJ; Lambin P
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):314-21. PubMed ID: 19100925
[TBL] [Abstract][Full Text] [Related]
8. Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
Krishnamurthy D; Weinberg V; Cunha JA; Hsu IC; Pouliot J
Brachytherapy; 2011; 10(6):461-5. PubMed ID: 21397569
[TBL] [Abstract][Full Text] [Related]
9. EPR/alanine dosimetry in LDR brachytherapy--a feasibility study.
Schultka K; Ciesielski B; Serkies K; Sawicki T; Tarnawska Z; Jassem J
Radiat Prot Dosimetry; 2006; 120(1-4):171-5. PubMed ID: 16565206
[TBL] [Abstract][Full Text] [Related]
10. Response of the alanine/ESR dosimeter to radiation from an Ir-192 HDR brachytherapy source.
Anton M; Hackel T; Zink K; von Voigts-Rhetz P; Selbach HJ
Phys Med Biol; 2015 Jan; 60(1):175-93. PubMed ID: 25489724
[TBL] [Abstract][Full Text] [Related]
11. Dose uncertainty in radiotherapy of patients with head and neck cancer measured by in vivo ESR/alanine dosimetry using a mouthpiece.
Wagner D; Anton M; Vorwerk H
Phys Med Biol; 2011 Mar; 56(5):1373-83. PubMed ID: 21297240
[TBL] [Abstract][Full Text] [Related]
12. A dosimetry method in the transverse plane of HDR Ir-192 brachytherapy source using gafchromic EBT2 film.
Uniyal SC; Sharma SD; Naithani UC
Phys Med; 2012 Apr; 28(2):129-33. PubMed ID: 21507693
[TBL] [Abstract][Full Text] [Related]
13. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
[TBL] [Abstract][Full Text] [Related]
14. Response of the alanine/ESR dosimetry system to MV X-rays relative to (60)Co radiation.
Anton M; Kapsch RP; Krystek M; Renner F
Phys Med Biol; 2008 May; 53(10):2753-70. PubMed ID: 18448875
[TBL] [Abstract][Full Text] [Related]
15. In vivo dosimetry with a linear MOSFET array to evaluate the urethra dose during permanent implant brachytherapy using iodine-125.
Bloemen-van Gurp EJ; Haanstra BK; Murrer LH; van Gils FC; Dekker AL; Mijnheer BJ; Lambin P
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1266-72. PubMed ID: 19665317
[TBL] [Abstract][Full Text] [Related]
16. Audit on source strength determination for HDR and PDR (192)Ir brachytherapy in Sweden.
Carlsson Tedgren A; Grindborg JE
Radiother Oncol; 2008 Jan; 86(1):126-30. PubMed ID: 18187219
[TBL] [Abstract][Full Text] [Related]
17. Suitability of microDiamond detectors for the determination of absorbed dose to water around high-dose-rate
Kaveckyte V; Malusek A; Benmakhlouf H; Alm Carlsson G; Carlsson Tedgren Å
Med Phys; 2018 Jan; 45(1):429-437. PubMed ID: 29171060
[TBL] [Abstract][Full Text] [Related]
18. Measurement of absorbed dose-to-water for an HDR (192)Ir source with ionization chambers in a sandwich setup.
Araki F; Kouno T; Ohno T; Kakei K; Yoshiyama F; Kawamura S
Med Phys; 2013 Sep; 40(9):092101. PubMed ID: 24007170
[TBL] [Abstract][Full Text] [Related]
19. An in vivo investigative protocol for HDR prostate brachytherapy using urethral and rectal thermoluminescence dosimetry.
Toye W; Das R; Kron T; Franich R; Johnston P; Duchesne G
Radiother Oncol; 2009 May; 91(2):243-8. PubMed ID: 18954914
[TBL] [Abstract][Full Text] [Related]
20. In regard to Anagnostopoulos et al.: In vivo thermoluminescence dosimetry dose verification of transperinal (192)Ir high dose rate brachytherapy using CT-based planning for the treatment of prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:1183-1191).
Duggan L; Bucci J; Kron T
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):911; author reply 911-2. PubMed ID: 15183495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
